Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers

Toll-like receptor 4 (TLR-4) is well known for its host innate immunity. Despite the fact that TLR-4 activation confers antitumor responses; emerging evidence suggests that TLR-4 is associated with tumor development and progression. It is now clear that overactivation of TLR-4, through various immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Mai, Chun Wai, Kang, Yew Beng, Pichika, Mallikarjuna Rao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821792/
https://www.ncbi.nlm.nih.gov/pubmed/24235843
http://dx.doi.org/10.2147/OTT.S50838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821792/
https://www.ncbi.nlm.nih.gov/pubmed/24235843
http://dx.doi.org/10.2147/OTT.S50838

Ejemplares similares